Calliditas Therapeutics AB American Depositary Shares
CALT
CALT was delisted on the 20th of September, 2024.
5 hedge funds and large institutions have $750K invested in Calliditas Therapeutics AB American Depositary Shares in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 16 closing their positions.
72% less funds holding
Funds holding: 18 → 5 (-13)
81% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 16
98% less capital invested
Capital invested by funds: $32.3M → $750K (-$31.5M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $15K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CGH
Crossmark Global Holdings
Houston,
Texas
|
+$636K |
| 2 |
AP
Advisors Preferred
Rockville,
Maryland
|
+$79.7K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$72K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$3.98K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$29.2M |
| 2 |
IIM
Ironwood Investment Management
Boston,
Massachusetts
|
-$999K |
| 3 |
Optiver Holding
Amsterdam,
Netherlands
|
-$871K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$419K |
| 5 |
PCM
PenderFund Capital Management
Vancouver,
British Columbia, Canada
|
-$320K |
CALT Hedge Fund Activity: Q3 2024 in Review
5 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q3 2024, worth a combined $750K — down 98% from $32.3M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of CALT and 3 opened new positions — a net loss of 13 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Crossmark Global Holdings, opening a new position worth an estimated $636K. The largest seller was BVF Inc, exiting entirely with an estimated $29.2M sold.
- 5 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q3 2024, down from 18 in Q2 2024.
- Funds reported $750K of Calliditas Therapeutics AB American Depositary Shares stock for Q3 2024, down 98% quarter-over-quarter.
- 3 funds opened new Calliditas Therapeutics AB American Depositary Shares positions in Q3 2024 and 16 closed out, a net change of -13 holders.
- The largest Calliditas Therapeutics AB American Depositary Shares buyer in Q3 2024 was Crossmark Global Holdings, an estimated $636K added.
- The largest Calliditas Therapeutics AB American Depositary Shares seller in Q3 2024 was BVF Inc, an estimated $29.2M sold.
Based on aggregated 13F filings for Q3 2024.